Shabnam Rashid
Patients with stable coronary artery disease with a fractional flow reserve (FFR) of >0.75 to 0.8 can be safely managed with medical therapy with lower major adverse cardiac events. This avoids the risks associated with percutaneous coronary intervention (PCI) including stent thrombosis and restenosis. In patients with an acute coronary syndrome (ACS) the value of FFR is unclear as maximal hyperemia is required. In patients with an ACS microvascular changes may prevent vasodilatation thus affecting the validity of FFR. Studies have shown that FFR can be safely performed with high accuracy if performed a few days after an infarct.